Late last winter, Lilly announced the results of a milestone clinical trial. Where does the company go from here?
The pharmaceutical firm has spent nearly three decades and $3 billion in an Ahab-like quest to develop the world’s first effective drug to attack Alzheimer’s. The search has consumed the careers of Eli Lilly and Company scientists and staffers as they try to cure a disease that afflicts a new victim in the United States every 66 seconds. And this month—when the results of a milestone clinical trial are revealed in a top-secret room in the company’s Indianapolis headquarters—the world will find out whether they got it right.
The Indianapolis pharmaceutical company targets age-related ailments as U.S. patents on some of its most profitable drugs expire.